Skip Navigation


Carcinogenesis Advance Access originally published online on June 25, 2008
Carcinogenesis 2008 29(8):1639-1647; doi:10.1093/carcin/bgn155
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/8/1639    most recent
bgn155v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Calvisi, D. F.
Right arrow Articles by Pascale, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calvisi, D. F.
Right arrow Articles by Pascale, R. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease

Diego F. Calvisi, Federico Pinna, Sara Ladu, Rossella Pellegrino, Maria R. Muroni, Maria M. Simile, Maddalena Frau, Maria L. Tomasi, Maria R. De Miglio, Maria A. Seddaiu, Lucia Daino, Valeria Sanna, Francesco Feo* and Rosa M. Pascale

Department of Biomedical Sciences, Division of Experimental Pathology and Oncology, University of Sassari, 07100 Sassari, Italy

* To whom correspondence should be addressed. Tel: +39 070228307; Fax: +39 070228485; Email: feo{at}uniss.it

Mounting evidence underlines the role of inducible nitric oxide synthase (iNOS) in hepatocellular carcinoma (HCC) development, but its functional interactions with pathways involved in HCC progression remain uninvestigated. Here, we analyzed in preneoplastic and neoplastic livers from Fisher 344 and Brown Norway rats, possessing different genetic predisposition to HCC, in transforming growth factor-{alpha} (TGF-{alpha}) and c-Myc–TGF-{alpha} transgenic mice, characterized by different susceptibility to HCC, and in human HCC: (i) iNOS function and interactions with nuclear factor-kB (NF-kB) and Ha-RAS/extracellular signal-regulated kinase (ERK) during hepatocarcinogenesis; (ii) influence of genetic predisposition to liver cancer on these pathways and role of these cascades in determining a susceptible or resistant phenotype and (iii) iNOS prognostic value in human HCC. We found progressive iNos induction in rat and mouse liver lesions, always at higher levels in the most aggressive models represented by HCC of rats genetically susceptible to hepatocarcinogenesis and c-Myc–TGF-{alpha} transgenic mice. iNOS, inhibitor of kB kinase/NF-kB and RAS/ERK upregulation was significantly higher in HCC with poorer prognosis (as defined by patients’ survival length) and positively correlated with tumor proliferation, genomic instability and microvascularization and negatively with apoptosis. Suppression of iNOS signaling by aminoguanidine led to decreased HCC growth and NF-kB and RAS/ERK expression and increased apoptosis both in vivo and in vitro. Conversely, block of NF-kB signaling by sulfasalazine or short interfering RNA (siRNA) or ERK signaling by UO126 caused iNOS downregulation in HCC cell lines. These findings indicate that iNOS cross talk with NF-kB and Ha-RAS/ERK cascades influences HCC growth and prognosis, suggesting that key component of iNOS signaling could represent important therapeutic targets for human HCC.

Abbreviations: AG, aminoguanidine; BN, Brown Norway; ERK, extracellular signal-regulated kinase; F344, Fisher 344; GS2, Glyco-SNAP-2; GTP, guanosine triphosphate; HCC, hepatocellular carcinoma; HCCB, hepatocellular carcinoma with better prognosis; HCCP, hepatocellular carcinoma with poorer prognosis; IFN-{gamma}, interferon-{gamma}; IKB, inhibitor of kB; IKK, inhibitor of kB kinase; IL, interleukin; iNOS, inducible nitric oxide synthase; mRNA, messenger RNA; MVD, microvessel density; NF-kB, nuclear factor-kB; NO•, nitric oxide; pRb, retinoblastoma protein; siRNA, short interfering RNA; SL, surrounding liver; Sulfa, sulfasalazine; TGF-{alpha}, transforming growth factor-{alpha}; TNF-{alpha}, tumor necrosis factor-{alpha}

Received March 28, 2008; revised May 19, 2008; accepted June 17, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
F. Feo, M. Frau, M. L. Tomasi, S. Brozzetti, and R. M. Pascale
Genetic and Epigenetic Control of Molecular Alterations in Hepatocellular Carcinoma
Experimental Biology and Medicine, July 1, 2009; 234(7): 726 - 736.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.